Cargando…

Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool

OBJECTIVE: Patients with ulcerative colitis (UC) diagnosed with low-grade dysplasia (LGD) have increased risk of developing advanced neoplasia (AN: high-grade dysplasia or colorectal cancer). We aimed to develop and validate a predictor of AN risk in patients with UC with LGD and create a visual web...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curtius, Kit, Kabir, Misha, Al Bakir, Ibrahim, Choi, Chang Ho Ryan, Hartono, Juanda L, Johnson, Michael, East, James E, Lindsay, James O, Vega, Roser, Thomas-Gibson, Siwan, Warusavitarne, Janindra, Wilson, Ana, Graham, Trevor A, Hart, Ailsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921573/ https://www.ncbi.nlm.nih.gov/pubmed/33990383 http://dx.doi.org/10.1136/gutjnl-2020-323546

Ejemplares similares

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2015)

Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2019)

Evolutionary history of human colitis-associated colorectal cancer
por: Baker, Ann-Marie, et al.
Publicado: (2019)

Optimising inflammatory bowel disease surveillance and dysplasia management—Where do we stand?
por: Al Bakir, Ibrahim, et al.
Publicado: (2022)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer
por: Choi, Chang-ho Ryan, et al.
Publicado: (2015)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trial
por: Münch, Andreas, et al.
Publicado: (2021)

Volume assessment magnetic resonance imaging technique for monitoring perianal Crohn’s fistulas
por: Lung, Phillip F. C., et al.
Publicado: (2018)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis
por: Masterson, Joanne C, et al.
Publicado: (2015)

Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
por: Sebastian, Shaji, et al.
Publicado: (2022)

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
por: Sheridan, Juliette, et al.
Publicado: (2018)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer
por: Corfe, Bernard M, et al.
Publicado: (2015)

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
por: Johansson, Malin E V, et al.
Publicado: (2014)

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
por: He, Xiaolong, et al.
Publicado: (2021)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy
por: Kayes, Tahrima, et al.
Publicado: (2021)

Treatment-refractory ulcerative colitis responsive to indigo naturalis
por: Saiki, Julie P, et al.
Publicado: (2021)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Hemidesmosome integrity protects the colon against colitis and colorectal cancer
por: De Arcangelis, Adèle, et al.
Publicado: (2017)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
por: van der Post, Sjoerd, et al.
Publicado: (2019)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Acute appendicitis and ulcerative colitis: a population-based sibling comparison study
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8pidi9cllvgtoi38vqlj74jo5q